The domestic pharmaceutical machinery industry is ushering in a new period of development opportunities, and two major problems need to be resolved urgently

The pharmaceutical equipment industry is the upstream of the pharmaceutical industry.
In recent years, influenced by the continuous release of favorable policies for the pharmaceutical industry and the pharmaceutical industry, the development of the entire pharmaceutical equipment industry has also begun to usher in more new opportunities
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) For example, the end of the pilot work of traditional Chinese medicine formula granules is imminent, and relevant pharmaceutical companies need to prepare for production capacity and production scale.
Therefore, the industry expects the demand for Chinese medicine formula granules related equipment and production lines Will usher in growth
.
In addition, under the "three-child concept", the demand for children's drugs may also grow further, and the production capacity of related pharmaceutical companies is expected to usher in a new round of expansion and upgrade, and this impact may also indirectly affect the upstream pharmaceutical equipment industry.
Bringing development opportunities.
.
.
The analysis believes that, on the whole, the domestic pharmaceutical machinery industry is in a new round of development opportunities.
In addition to favorable policy support, under the accelerated upgrading of the pharmaceutical industry and the rapid development of emerging fields such as monoclonal antibodies , The pharmaceutical equipment industry is expected to continue its growth momentum for a long time
.
In fact, in the first three quarters of 2021, the overall performance of the pharmaceutical equipment industry has been improving, especially in the first half of the year, in the semi-annual reports of many pharmaceutical machinery companies, their performance has doubled
.
For example, Chutian Technology made a profit of approximately 236 million yuan in the first half of 2021, a year-on-year increase of 1321.
22%; Tofflon achieved operating income of 1.
81 billion yuan, a year-on-year increase of 52.
22%; while Xinlai made a profit of approximately 67.
89 million yuan, a year-on-year increase of 101.
1.
%
.
It can be clearly seen from the above that the development of the domestic pharmaceutical equipment industry is continuing to improve
.
The industry predicts that in the future, as the pharmaceutical equipment market enters the overall stability, and with the continuous acceleration of the upstream pharmaceutical industry, the Chinese pharmaceutical equipment market may reach 4.
58 billion US dollars in 2025, with a compound growth rate of 8.
1%
.
However, it is worth noting that the industry has also pointed out that while the domestic pharmaceutical equipment industry is ushering in new opportunities, there are still many challenges
.
For example, in terms of internationalization, domestic enterprises still have problems such as low level of equipment informatization and low competitiveness in the process of moving to the international stage.

.
In addition, although high-end pharmaceutical equipment has become a new driving force for the performance growth of domestic pharmaceutical companies, the current problems of insufficient domestic high-end equipment and lack of high-tech content still exist, and the right to speak is also urgently needed to be improved
.
Regarding the above problems, the industry has proposed that relevant companies need to continuously break through the core technology bottlenecks and improve R&D and design capabilities to grasp the industry’s "pulse
.
" Moreover, in addition to continuous efforts in product technology and quality, pharmaceutical machinery companies also need to strengthen the information construction of pharmaceutical equipment management and maintenance by vigorously training professional talents, and establish effective management work models
.
While meeting the greater demand of pharmaceutical companies for high-end equipment, we will further develop in-depth internationalization
.
In general, the above two major issues are the main obstacles to the high-quality development of China's pharmaceutical equipment industry, and require key research by industries and enterprises
.
In fact, as far as the author knows, many domestic pharmaceutical giants are already ready to go.
Under the trend of accelerating domestic substitution process, they are increasing R&D investment, pursuing technological breakthroughs and development, and improving service levels.
The more high-end products are exported overseas, the related performance has also increased significantly
.